RVTY REVVITY, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 31791 · Fiscal year ends 12/29
Financial factors as of 2026-10-04 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.6%
TTM net income YoY6.6%
TTM EPS YoY12.6%
Revenue 3-yr CAGR1.7%
Net income 3-yr CAGR-30.1%
Margins
Gross margin—
Operating margin12.6%
Net margin8.6%
FCF margin20.1%
EBITDA margin20.9%
Returns
ROE3.5%
ROA2.1%
ROIC (approx.)3.5%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.36x
Current ratio2.65x
Interest coverage4.04x
Cash quality & payout
Operating cash flow / net income2.59x
Accruals ratio-3.4%
Payout ratio12.4%
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-10-04 | 2026Q22026-07-05 | 2026Q12026-04-05 | 2025Q4*2025-12-28 | 2025Q32025-09-28 | 2025Q22025-06-29 | 2025Q12025-03-30 | 2024Q4*2024-12-29 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $728.90M | $729.69M | $711.12M | $772.06M | $698.95M | $720.28M | $664.76M | $729.37M |
| Cost of revenue | $310.32M | $312.82M | $323.46M | — | $324.35M | $327.73M | $289.22M | — |
| Gross profit | $418.58M | $416.87M | $387.65M | — | $374.60M | $392.56M | $375.55M | — |
| R&D expense | $48.11M | $48.97M | $57.89M | $58.18M | $50.80M | $53.27M | $53.60M | $49.21M |
| SG&A expense | $275.33M | $278.58M | $253.88M | $251.73M | $241.91M | $248.53M | $249.72M | $244.33M |
| Operating income | $95.14M | $89.32M | $75.89M | $111.75M | $81.90M | $90.76M | $72.23M | $118.75M |
| Interest expense | $20.81M | $22.99M | $24.72M | $23.51M | $22.77M | $22.94M | $22.96M | $22.78M |
| Pretax income | $77.68M | $63.53M | $49.99M | $91.56M | $55.69M | $68.65M | $52.38M | $94.56M |
| Income tax | $15.06M | $10.05M | $9.10M | -$4.21M | $8.46M | $13.43M | $10.71M | $6.17M |
| Net income | $62.30M | $51.82M | $40.72M | $98.36M | $46.65M | $53.95M | $42.24M | $94.64M |
| EBITDA | $113.37M | $106.48M | $180.94M | $214.83M | $99.88M | $108.25M | $169.65M | $223.78M |
| EPS (basic) | 0.56 | 0.47 | 0.36 | — | 0.40 | 0.46 | 0.35 | — |
| EPS (diluted) | 0.56 | 0.47 | 0.36 | — | 0.40 | 0.46 | 0.35 | — |
| Dividends declared per share | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Weighted avg. shares (diluted) | 111.83M | 111.63M | 111.88M | — | 115.46M | 117.54M | 120.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $592.80M | $1.02B | $860.32M | $919.86M | $931.39M | $991.85M | $1.14B | $1.16B |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $687.33M | $709.17M | $691.38M | $744.67M | $680.26M | $661.14M | $617.42M | $632.40M |
| Inventory | $388.85M | $378.50M | $387.50M | $379.50M | $379.92M | $388.47M | $381.31M | $367.59M |
| Current assets | $1.86B | $2.30B | $2.13B | $2.24B | $2.14B | $2.24B | $2.32B | $2.35B |
| PP&E, net | $450.87M | $456.25M | $465.64M | $479.25M | $497.09M | $499.03M | $486.71M | $482.22M |
| Goodwill | $6.59B | $6.61B | $6.61B | $6.61B | $6.60B | $6.61B | $6.51B | $6.46B |
| Intangibles | $2.14B | $2.22B | $2.31B | $2.35B | $2.43B | $2.51B | $2.57B | $2.64B |
| Total assets | $11.49B | $12.05B | $12.00B | $12.17B | $12.14B | $12.36B | $12.36B | $12.39B |
| Current liabilities | $701.48M | $1.28B | $1.24B | $1.33B | $1.22B | $671.81M | $648.19M | $653.10M |
| Short-term debt | $0 | $572.16M | $575.83M | $588.83M | $583.84M | $230,000 | $242,000 | $242,000 |
| Long-term debt | $2.63B | $2.63B | $2.63B | $2.63B | $2.63B | $3.21B | $3.17B | $3.15B |
| Total debt | $2.63B | $3.21B | $3.21B | $3.22B | $3.21B | $3.21B | $3.17B | $3.15B |
| Total liabilities | $4.22B | $4.82B | $4.81B | $4.92B | $4.76B | $4.81B | $4.72B | $4.73B |
| Shareholders' equity | $7.27B | $7.23B | $7.18B | $7.25B | $7.38B | $7.56B | $7.64B | $7.67B |
| Net debt | $2.04B | $2.18B | $2.35B | $2.30B | $2.28B | $2.22B | $2.03B | $1.99B |
| Shares outstanding | 111.62M | 111.58M | 111.63M | 112.28M | 114.03M | 116.33M | 119.41M | 120.65M |
| Cash flow statement | ||||||||
| Operating cash flow | $166.70M | $191.94M | $115.23M | $181.96M | $138.50M | $134.32M | $128.16M | $174.23M |
| Capital expenditure | $14.35M | $11.07M | $19.77M | $20.17M | $18.50M | $18.87M | $15.98M | $24.45M |
| Free cash flow | $152.36M | $180.87M | $95.45M | $161.79M | $120.00M | $115.45M | $112.17M | $149.78M |
| Investing cash flow | -$15.60M | -$3.50M | -$78.27M | -$20.45M | $18.97M | -$9.49M | -$6.38M | -$17.33M |
| Financing cash flow | -$575.61M | -$23.16M | -$88.89M | -$176.31M | -$215.07M | -$302.48M | -$163.66M | -$192.99M |
| Depreciation & amortization | $18.23M | $17.17M | $105.06M | $103.08M | $17.98M | $17.49M | $97.42M | $105.03M |
| Stock-based compensation | $9.75M | $10.73M | $8.71M | -$4.07M | $9.05M | $10.13M | $7.73M | $5.05M |
| Dividends paid | $7.81M | $7.81M | $7.84M | $7.96M | $8.13M | $8.28M | $8.43M | $8.54M |
| Share buybacks | $95,000 | $15.99M | $86.50M | $168.28M | $205.03M | $293.91M | $153.59M | $185.16M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.